Prostate cancer: PSMA PET/CT-targeted biopsy improves detection
New research published in the Journal of Nuclear Medicine suggests that combining PSMA PET/CT scans with traditional biopsies significantly improves prostate cancer detection. This approach helps identify clinically significant tumors that might be missed by MRI alone.
Why it matters
Improving diagnostic accuracy for prostate cancer can lead to better patient outcomes and prevent unnecessary repeated procedures.
Dynamic total-body PSMA PET. 76-year-old patient with prostate cancer (PCa) (PI-RADS 2; initial PSA, 19.7; PSA density, 0.82). Representative reconstructed dynamic total-body PET maximum-intensity projection images (A) and transaxial fused PET/CT images (B). Red arrows indicate area of intense uptake in prostate (PRIMARY score 5; ISUP 4 after biopsy; SUV max , 55.6).
According to new research published in the Journal of Nuclear Medicine , combining the two biopsy approaches is even more effective, nearly doubling the detection rate. This strategy may help physicians identify clinically significant cancers that would otherwise be difficult to detect, while potentially avoiding unnecessary procedures in appropriately selected patients.
A negative or unclear MRI does not completely rule out clinically significant prostate cancer. As a result, some men may undergo repeated or extensive biopsies, while relevant tumors may still be missed
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in